Summary
Merck & Co., Inc. reported strong financial results for the quarter and six months ended June 30, 2024. Sales increased by 7% to $16.1 billion in the second quarter and 8% to $31.9 billion year-to-date, driven primarily by growth in the oncology and vaccines segments, particularly from Keytruda and Gardasil/Gardasil 9. Net income attributable to Merck & Co., Inc. significantly improved to $5.5 billion ($2.15 per share) in the second quarter, compared to a net loss of $6.0 billion ($2.35 per share) in the prior year period. This turnaround is largely due to the absence of substantial acquisition-related charges that impacted the prior year. The company continued its strategic growth through significant business development, including the acquisition of Elanco's aqua business and EyeBio in July 2024, and Harpoon Therapeutics in March 2024. These investments, while impacting R&D expenses, are positioned to bolster the company's pipeline and future growth. Merck also announced a new $4.0 billion restructuring program aimed at optimizing its manufacturing network, expected to yield substantial annual cost savings by 2031. The company's liquidity remains strong, with robust operating cash flow supporting its strategic initiatives and shareholder returns, including dividends and share repurchases.
Financial Highlights
55 data points| Revenue | $16.11B |
| Cost of Revenue | $3.75B |
| Gross Profit | $12.37B |
| R&D Expenses | $3.50B |
| SG&A Expenses | $2.74B |
| Net Income | $5.46B |
| EPS (Basic) | $2.15 |
| EPS (Diluted) | $2.14 |
| Shares Outstanding (Basic) | 2.53B |
| Shares Outstanding (Diluted) | 2.54B |
Key Highlights
- 1Sales increased 7% to $16.1 billion in Q2 2024 and 8% to $31.9 billion year-to-date, driven by Keytruda and Gardasil/Gardasil 9.
- 2Net income attributable to Merck & Co., Inc. was $5.5 billion ($2.15 per share) in Q2 2024, a significant improvement from a net loss of $6.0 billion ($2.35 per share) in Q2 2023, primarily due to the absence of large acquisition charges.
- 3Research and Development (R&D) expenses decreased significantly to $3.5 billion in Q2 2024 from $13.3 billion in Q2 2023, mainly due to the absence of the $10.2 billion charge for the Prometheus acquisition in the prior year.
- 4The company made substantial business development moves in Q3 2024 with the acquisition of Elanco's aqua business and EyeBio, and in Q1 2024 with the acquisition of Harpoon Therapeutics, indicating continued investment in pipeline expansion.
- 5Merck initiated a new $4.0 billion restructuring program in January 2024 to optimize its manufacturing network, expected to generate approximately $750 million in annual net cost savings by 2031.
- 6Operating cash flow remains strong, providing $8.7 billion in the first six months of 2024, supporting investments in business development, capital expenditures, and shareholder returns.
- 7The company is facing ongoing pricing pressures and regulatory scrutiny, particularly related to the Inflation Reduction Act (IRA) and its impact on Januvia, with a lawsuit filed against the U.S. government.